We are excited to welcome Quris AI, the latest company to join the AstraZeneca BioVentureHub at the Gothenburg R&D site.
Quris AI combines Bio and AI capabilities to provide safer, more effective, and more personalized drugs to patients faster, leveraging their patented AI-driven patient-on-chip platform.
Led by a team of pioneers in machine learning, big data, organ-on-chip, biotech, genomics, technology, and pharma, Quris brings together the best of both worlds: Bio and AI.
By joining the BioVentureHub, Quris will form a new, fast-growing team, situated at the AstraZeneca Gothenburg R&D site in Sweden, with access to state-of-the-art facilities, infrastructure, R&D knowledge, and expertise.
We are looking forward to seeing the team join in, grow and contribute to, and benefit from, the “dare-to-share” culture in the BioVentureHub community.
It is also exciting to collaborate within the A.Catalyst Network, a dynamic AstraZeneca network of solutioners and innovative minds from around the globe, and in this particular case the BeyondBio innovation hub.
Warm welcome!
#Welcome #NewCompany #Quris #Bio #AI #PatientOnChip #ACatalystNetwork #BeyondBio #AccesTo #GrowingInnovationTogether #NewKidsInTown Magnus R. Björsne, Isaac Bentwich, Amir Bein, Sharon Ein-Gal, Ulrika Edvardsson, Robert Börjes, Pernilla Isberg, Emma Wiesel, Erica Woodrow, Anders Persson, Madeleine Thun , Mia Ekdahl